

GEORGIA MEDICAID FEE-FOR-SERVICE VASODILATORS, CORONARY PA SUMMARY

Preferred	Non-Preferred
Dilatrate SR (isosorbide dinitrate SR)	BiDil (isosorbide dinitrate/hydralazine hydrochloride)
Isordil (isosorbide dinitrate)	GoNitro (nitroglycerin sublingual powder)
Isosorbide dinitrate generic	Nitroglycerin lingual spray generic
Isosorbide mononitrate generic	Verquvo (vericiguat)
Isosorbide mononitrate ER generic	
Minitran (nitroglycerin transdermal patch)	
Nitro-Bid (nitroglycerin ointment)	
Nitro-Dur 0.8 mg/hour (nitroglycerin transdermal patch)	
Nitroglycerin transdermal patch generic	
Nitroglycerin sublingual tablets generic	
Nitrostat (nitroglycerin sublingual tablets)	

SR=sustained release; ER=extended release

LENGTH OF AUTHORIZATION: 1 year

PA CRITERIA:

BiDil

❖ Prescriber must submit a written letter of medical necessity stating the reasons the preferred products, generic isosorbide dinitrate and generic hydralazine, are not appropriate for the member.

GoNitro and Nitroglycerin Lingual Spray Generic

❖ Prescriber must submit a written letter of medical necessity stating the reasons the preferred products, generic nitroglycerin sublingual tablets and brand Nitrostat sublingual tablets, are not appropriate for the member.

Verquvo

❖ Approvable for members 18 years of age and older with a diagnosis of New York Heart Association (NYHA) Class II-IV or American College of Cardiology/American Heart Association (ACC/AHA) Stage C-D chronic heart failure and left ventricular ejection fraction (LVEF) <45% who have been hospitalized for heart failure within the past 6 months or received an outpatient intravenous (IV) diuretic within the past 3 months

4Λ	D	
*	Member must have experienced an inadequate response, allergies,	
	co	ntraindications, drug-drug interactions or intolerable side effects with at
	lea	st one medication in at least three of the following classes:
		Sodium-glucose transport protein 2 [SGLT-2] inhibitors (e.g.,
		dapagliflozin [Farxiga], canagliflozin [Invokana], empagliflozin
		[Jardiance])
		Angiotensin-converting enzyme [ACE] inhibitors (e.g., enalapril,
		lisinopril), Angiotensin receptor blockers [ARBs] (e.g., losartan,



valsartan, candesartan) or Angiotensin receptor-neprilysin inhibitor
[ARNI] (e.g., sacubitril/valsartan [Entresto])
Beta blockers (e.g., bisoprolol, carvedilol, metoprolol succinate)
Aldosterone antagonists (e.g., spironolactone, eplerenone)

EXCEPTIONS:

- * Exceptions to these conditions of coverage are considered through the prior authorization process.
- ❖ The Prior Authorization process may be initiated by calling OptumRx at 1-866-525-5827.

PREFERRED DRUG LIST:

❖ For online access to the Preferred Drug List (PDL), please go to http://dch.georgia.gov/preferred-drug-lists.

PA AND APPEAL PROCESS:

❖ For online access to the PA process, please go to <u>www.dch.georgia.gov/prior-authorization-process-and-criteria</u> and click on Prior Authorization (PA) Request Process Guide.

QUANTITY LEVEL LIMITATIONS:

❖ For online access to the current Quantity Level Limits (QLL), please go to www.mmis.georgia.gov/portal, highlight Provider Information and click on Provider Manuals. Scroll to the page with Pharmacy Services and select that manual.